Drugmakers defend patent settlements in Supreme Court case

03/11/2013 | Politico (Washington, D.C.)

Makers of generic and brand-name drugs say that agreements to keep generic drugs off the market for a certain period do not cost consumers more, but in fact save money by avoiding expensive patent litigation. The Federal Trade Commission is suing to have so-called pay-for-delay deals ruled anti-competitive.

View Full Article in:

Politico (Washington, D.C.)